Definitions

1. Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. (Web site)
2. Mesalazine is an anti-inflammatory drug used in inflammatory bowel conditions, such as ulcerative colitis and crohn's disease. (Web site)
3. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. (Web site)
4. Mesalazine is a 5-aminosalicylic acid compound that is the primary treatment for mild-to-moderate ulcerative colitis.
5. Mesalazine (5-ASA) is a potent inhibitor of their synthesis in the mucosa and could therefore be of some interest in preventing ARE.

Once-Daily Mesalazine Formulations

1. This editorial will focus on the efficacy and tolerability of the new, once-daily mesalazine formulations.

H15

1. The per protocol population included 44 patients treated with H15 and 39 patients treated with mesalazine. (Web site)

Mesalazine Formulations

1. The efficacy of the other new mesalazine formulations for the maintenance therapy in mild-to-moderate UC is summarized in Table 2.

Oral Mesalazine

1. Reactions reported during treatment with oral mesalazine are listed in the table below. (Web site)

Mesalazine Group

1. The frequency of patients with an endoscopic remission was higher in the mesalazine group (57%) than in the placebo group (37%). (Web site)
2. The respective values for the per protocol population (PP) were 59.9% examined in the budesonide group and 77.5% in the mesalazine group (p < 0.02). (Web site)

Mesalazine Foam Enema

1. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.

Literature

1. The efficacy of mesalazine in the overall heterozygous CD population is inconsistent, both in literature and in practice. (Web site)

Active

1. Two phase III studies have already evaluated MMX mesalazine in patients with active, mild-to-moderate ulcerative colitis. (Web site)
2. Recently, MMX mesalazine has been approved in the US for the induction of remission in adult patients with active, mild-to-moderate ulcerative colitis.
3. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. (Web site)

Combination

1. He prescribed mesalazine 1 g twice daily in combination with Saccharomyces boulardii for six months; only one patient relapsed.

Tablets

1. Salofalk Gr (Mesalazine) Imigran (Imitrex) Tablets are the original drawing board up anti-migraine medicine.

Safety

1. This editorial summarizes the available literature on the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.

Conclusion

1. CONCLUSION: The new mesalazine gel enema is efficacious and significantly better tolerated than the mesalazine foam enema. (Web site)

Aim

1. Aim To provide more precise estimates of the efficacy of MMX mesalazine over placebo by combining the patient populations from the two phase III studies. (Web site)
2. AIM: To compare the efficacy of oral mesalazine vs. (Web site)
3. AIM: A novel formulation of mesalazine pellets with delayed and prolonged release characteristics was compared with conventional Eudragit L-coated tablets. (Web site)

Background

1. BACKGROUND: Formulations containing 5-aminosalicylic acid, such as mesalazine, are the gold standard of treatment for mild-to-moderate ulcerative colitis.

Low Frequency

1. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. (Web site)

Results

1. RESULTS: Clinical remission (intention-to-treat analysis) at week 4 was 63.5% for budesonide enemas and 77.2% for mesalazine enemas (p < 0.05). (Web site)
2. RESULTS: Clinical remission was more frequent in the mesalazine group than the placebo group (65% vs. (Web site)

Trial

1. Eleven patients, nine receiving placebo and two receiving 1.5 g mesalazine, withdrew during trial, mostly because of worsening of symptoms. (Web site)

Prevention

1. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. (Web site)

Combination Therapy

1. After 25 years of mesalazine use, it is clear that the value of combination therapy, whether beneficial or detrimental, remains to be fully elucidated. (Web site)
2. Combination therapy of oral and rectal mesalazine has been investigated. (Web site)

Complications

1. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.

Crohn

1. Her Crohn’s disease was previously well controlled on mesalazine, with few exacerbations and no admissions to hospital.

Suppository

1. Recently a mesalazine 1 g suppository (Pentasa) has been developed.

Standard Treatment

1. H 15 was tested on non-inferiority compared to standard treatment with mesalazine. (Web site)
2. Boswellia was tested on non-inferiority compared to standard treatment with mesalazine. (Web site)

Ulcerative Colitis

1. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
2. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.

Moderately Active Ulcerative Colitis

1. Rectal formulations of mesalazine are the treatment of choice in mildly to moderately active ulcerative colitis. (Web site)
2. CONCLUSIONS: Mesalazine pellets are as effective as tablets in the treatment of mild to moderately active ulcerative colitis.

Maintaining Remission

1. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
2. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. (Web site)

Asacol

1. Mesalazine, also known as 5-aminosalicylic acid, mesalamine, or 5-ASA. Brand name formulations include Asacol, Pentasa, Mezavant, Lialda, and Salofalk.
2. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. (Web site)

Distal Ulcerative Colitis

1. BACKGROUND: Mesalazine enemas are of well proven efficacy for the topical treatment of distal ulcerative colitis. (Web site)

Balsalazide

1. The adverse effects of balsalazide and mesalazine are similar. (Web site)

Sulphasalazine

1. INTERVENTIONS: Coated mesalazine (Mesasal) 1.5 g daily or sulphasalazine 3.0 g daily for eight weeks. (Web site)

Placebo Groups

1. RESULTS: It was found that 25 of 48 subjects v 18 of 47 remained in remission in the mesalazine and placebo groups respectively. (Web site)

Study

1. AIM: This study compared a foam enema (2 g mesalazine per day, Claversal Foam) with a standard liquid enema (4 g mesalazine per day, Salofalk enema).

Patients

1. Rao, SS, Cann, PA, Holdsworth, CD. Clinical experience of the tolerance of mesalazine and Olsalazine in patients intolerant of sulphasalazine. (Web site)
2. In one study it was as effective as mesalazine for patients with mild to moderate Crohn's disease.
3. After obtaining informed consent, patients were randomized to three treatment groups: 500 mg mesalazine b.i.d.

Therapy

1. BACKGROUND: Therapy for active left sided ulcerative colitis (UC) usually involves topical application of mesalazine or budesonide. (Web site)
2. CONCLUSIONS: The study confirms that therapy with H15 is not inferior to mesalazine. (Web site)
3. Rectally administered mesalazine (5-aminosalicylic acid) is a recognized therapy for distal ulcerative colitis. (Web site)

Comparison

1. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. (Web site)
2. The secondary efficacy endpoints confirm the assessment of the comparison of H15 and mesalazine. (Web site)
3. The secondary efficacy endpoints confirm the assessment of the comparison of Boswellia and mesalazine. (Web site)

Randomized

1. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
2. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. (Web site)
3. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. (Web site)

Azathioprine

1. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Sulfasalazine

1. Most patients with adverse effects from sulfasalazine will tolerate mesalazine.
2. Two trials that compared 6-mercaptopurine to mesalazine, or azathioprine to sulfasalazine showed significant heterogeneity. (Web site)
3. The subjects received oral azathioprine or 6-mercaptopurine, placebo (fake pills) or standard maintenance treatment (mesalazine or sulfasalazine). (Web site)

Enema

1. CONCLUSIONS: Beclomethasone diproprionate and mesalazine enema and foam show a comparable tolerability and efficacy in mild active distal ulcerative colitis. (Web site)
2. BACKGROUND: The association of oral 5-aminosalicylic acid (mesalazine) and enema is effective in treatment of mild-moderate forms of ulcerative colitis. (Web site)

Placebo

1. We anticipate a reduction in the amount of inflammation, bowel nerve changes and symptoms in patients taking mesalazine compare to those taking the placebo. (Web site)
2. CONCLUSIONS: Mesalazine foam enema was well-tolerated and was more effective than placebo in the treatment of patients with distal ulcerative colitis. (Web site)
3. During the initial four weeks, they additionally received an enema at bedtime containing 1 g of mesalazine or placebo.

Efficacy

1. Efficacy of mesalazine was never tested in collagenous colitis by placebo-controlled trials. (Web site)
2. AIM: To compare the efficacy and safety of budesonide enema and mesalazine enema in the treatment of active left sided ulcerative colitis. (Web site)
3. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. (Web site)

Suppositories

1. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. (Web site)
2. BACKGROUND: Mesalazine suppositories at 500 mg b.d.
3. CONCLUSION: Mesalazine suppositories 1 g three times a week are effective for preventing relapses of cryptogenetic proctitis. (Web site)

Maintenance Treatment

1. CONCLUSION: Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD. (Web site)
2. CONCLUSIONS: The results of this study confirm the therapeutic efficacy of mesalazine suppositories in the maintenance treatment of ulcerative proctitis.
3. Topical mesalazine (suppositories or enemas) also is effective in maintenance treatment. (Web site)

Treatment

1. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: Randomized controlled trial.
2. The CDAI between the status of enrolment and end of therapy after treatment with Boswellia was reduced by 90 and after therapy with mesalazine by 53 scores.
3. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. (Web site)

Maintenance Therapy

1. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis.
2. Sulfasalazine and mesalazine remain the first-choice drugs for the maintenance therapy of distal ulcerative colitis. (Web site)
3. Maintenance therapy with mesalazine is also well documented[152], although it remains contentious as to which dosage and dosing frequency are optimal. (Web site)

Remission

1. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. (Web site)
2. At the end of the study 62% were in remission compared to 37% of the patients taking mesalazine. (Web site)
3. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission. (Web site)

Categories

1. Symptoms > Pain > Abdominal Pain > Ulcerative Colitis
2. Maintenance Therapy
3. Maintenance Treatment
4. Efficacy
5. Crohn's Disease

Related Keywords

* Active Ulcerative Colitis

1. Books about "Mesalazine" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -